BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raja H, Matteson EL, Michet CJ, Smith JR, Pulido JS. Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding. Transl Vis Sci Technol 2012;1:6. [PMID: 24049706 DOI: 10.1167/tvst.1.2.6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Williams M, Chakravarty EF. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy. Curr Opin Rheumatol. 2014;26:341-346. [PMID: 24663107 DOI: 10.1097/bor.0000000000000046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Alijotas-reig J, Esteve-valverde E, Ferrer-oliveras R. Tratamiento de las gestantes con enfermedades reumáticas o autoinmunitarias sistémicas con fármacos inmunodepresores y biológicos. Medicina Clínica 2016;147:352-60. [DOI: 10.1016/j.medcli.2016.05.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
3 Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. Current Opinion in Rheumatology 2014;26:354-60. [DOI: 10.1097/bor.0000000000000055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 3.9] [Reference Citation Analysis]
4 Jinesh S. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology. 2015;23:71-77. [PMID: 25687751 DOI: 10.1007/s10787-015-0229-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
5 Birru Talabi M, Eudy AM, Jayasundara M, Haroun T, Nowell WB, Curtis JR, Crow-Hercher R, White W, Ginsberg S, Clowse MEB. Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis. ACR Open Rheumatol 2021;3:475-83. [PMID: 34114738 DOI: 10.1002/acr2.11240] [Reference Citation Analysis]
6 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
7 Willekens B, Kleffner I. Susac syndrome and pregnancy: a review of published cases and considerations for patient management. Ther Adv Neurol Disord 2021;14:1756286420981352. [PMID: 33796140 DOI: 10.1177/1756286420981352] [Reference Citation Analysis]
8 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-2038. [PMID: 27156434 DOI: 10.1016/s0140-6736(16)30173-8] [Cited by in Crossref: 1387] [Cited by in F6Publishing: 663] [Article Influence: 277.4] [Reference Citation Analysis]
9 Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7-12. [PMID: 27123565 DOI: 10.1016/j.jri.2016.04.284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]